<div id="readability-page-1"><div><p>Mabwell announced that the first patient has been dosed in the Phase I/II clinical trial of its independently developed novel CDH17-targeting antibody-drug conjugate (ADC) (R&amp;D code: 7MW4911) for advanced solid tumors. This Phase I/II clinical trial (CTR20254163) aims to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of 7MW4911 in patients with advanced solid tumors. Previously, 7MW4911 had received IND clearance from FDA to initiate a Phase I/II clinical trial for advanced colorectal cancer and other advanced gastrointestinal tumors (NCT07216560).</p><p>7MW4911 is a novel CDH17-targeted ADC developed by Mabwell based on its proprietary IDDC?? platform. It is composed of a highly specific CDH17 monoclonal antibody capable of efficient internalization into tumor cells, a novel cleavable linker with high plasma stability, and a proprietary DNA topoisomerase I inhibitor payload, MF-6, specifically designed to overcome the multidrug resistance.</p><p>Preclinical studies demonstrated that 7MW4911 exhibited potent antitumor activity in CDX/PDX models of various gastrointestinal tumors. In multidrug-resistant models, its antitumor effect was significantly superior to MMAE/DXd-based ADCs, and it was able to reverse tumor progression following treatment with such ADCs, highlighting its advantage in treating resistant tumors. Relevant research findings have been published in the 2025 AACR and the internationally renowned journal Cell Reports Medicine (July 2025).</p></div></div>

迈威生物-U

<p>迈威生物-U 宣布其新型 CDH17 靶向 ADC 7MW4911 在针对晚期实体瘤的 I/II 期临床试验中首次给药。该试验旨在评估 7MW4911 的安全性、耐受性、药代动力学和初步疗效。前临床研究显示其具有强大的抗肿瘤活性，特别是在多药耐药模型中。7MW4911 之前已获得 FDA 的新药临床试验（IND）批准，用于晚期结直肠和胃肠肿瘤</p>

迈威生物-U 宣布首例患者接受新型 CDH17 靶向 ADC 药物 7MW4911 的给药